NCT00185965已完成1 期
Le23 CPG: A Phase 1-2 Study of Intratumoral Injection of CPG 7909, A TLR 9 Agonist, Combined With Local Radiation in Recurrent Low-Grade Lymphomas
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Ronald Levy
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- Objective Response Rate (ORR)
研究概览
简要总结
Brief summary TBD
详细描述
This is a single institution phase 1-2 trial to evaluate the safety, feasibility and efficacy of CpG injections (4 intratumoral injections followed by 6 peri-tumoral injections) combined with local irradiation in patients with recurrent low-grade lymphomas.
Patients will receive low-dose radiotherapy to a single tumor site on days 1 and 2 (2 Gy each day). CpG injections will be administered into the same tumor site within the 24 hours before and the 24 hours after the radiation, and on days 8 and 15. Weekly doses of CpG will be then administered subcutaneously in the region of previous injections for 6 additional doses.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must meet all of the following criteria in order to be eligible for entry into the trial.
- •Biopsy confirmed low-grade B-cell lymphoma of any initial stage or mycosis fungoides of stage IB-IVA. B-cell lymphoma patients must have failed at least one prior treatment. Mycosis fungoides patients must have failed or have been intolerant of at least 2 topical or one systemic treatment.
- •Patients must have at least one site of disease that is accessible for intratumoral injection of CpG percutaneously
- •Tumor specimens must be available for immunological studies either from a previous biopsy or a new biopsy obtained before the initiation of the treatment.
- •Patients must have measurable disease other than the injection site or biopsy site.
- •18 years of age or older
- •Karnofsky Performance Status (KPS) of >
- •Adequate bone marrow function: WBC>4,000uL, hemoglobin > 10g/dL; platelet count >100,000/mm3; ANC>
- •Adequate hepatic function: bilirubin <= 1.5 mg/dL; SGOT/SGPT<3xupper limit of normal
- •Adequate renal function: serum creatinine <= 2.0mg/dL.
- •Required wash out periods for prior therapy:
- •Topical therapy: 2 weeks
- •Chemotherapy: 4 weeks
- •Radiotherapy (including photo therapy): 4 weeks
- •Systemic biological therapy for mycosis fungoides: 4 weeks
- •Other investigational therapy: 4weeks
- •Rituximab: 12 weeks
- •Patients of reproductive potential and their partners must agree to use an effective (>90% reliability) form of contraception during the study and for 4 weeks following the last study drug administration.
- •Women of reproductive potential must have negative urine pregnancy test.
- •Life expectancy greater than 4 months.
- •Able to comply with the treatment schedule.
排除标准
- •A patient may not be enrolled in the trial if any of the following criteria are met.
- •Pre-existing autoimmune or antibody mediated disease including: systemic lupus, erythematosus, rheumatoid arthritis, multiple sclerosis, Sjogren's syndrome, autoimmune thrombocytopenia, but excluding controlled thyroid disease, or the presence of autoantibodies without clinical autoimmune disease.
- •Known history of human immunodeficiency virus (HIV), hepatitis B or hepatitis C (active, prior treatment, or both).
- •Patients with active infection or with a fever >38.50 C within three days prior to the first scheduled treatment.
- •CNS metastases
- •Prior malignancy (active within 5 years of screening) except basal cell or completely excised non-invasive squamous cell carcinoma of the skin, or in situ squamous cell carcinoma of the cervix.
- •History of allergic reactions attributed to compounds of similar composition to CpG 7909
- •Current anticoagulant therapy (ASA<= 325mg/day allowed).
- •Significant cardiovascular disease (i.e. NYHA class 3 congestive heart failure; myocardial infarction with the past 6 months; unstable angina; coronary angioplasty with the past 6 months; uncontrolled atrial or ventricular cardiac arrhythmias).
- •Pregnant or lactating.
- •Any other medical history, including laboratory results, deemed by the investigator to be likely to interfere with their participation in the study, or to interfere with the interpretation of the results.
研究组 & 干预措施
Lymphoma, B-cell low-grade (BCL)
Experimental
Recurrent low-grade B-cell lymphoma patients (at least one prior treatment failure)
干预措施: CPG 7909 (Drug)
Mycosis fungoides (MF)
Experimental
Mycosis fungoides patients must have failed or have been intolerant of at least 1 topical or 1 systemic treatment
Recurrent mycosis fungoides patients (at least one prior failure of topical or systemic treatment)
干预措施: CPG 7909 (Drug)
结局指标
主要结局
Objective Response Rate (ORR)
时间窗: 12 weeks
Objective Response Rate (ORR) consisting of Complete Response (CR) + Partial Response (PR), not including Stable Disease (SD)
次要结局
未报告次要终点
研究者
Ronald Levy
Robert K. and Helen K. Summy Professor in the School of Medicine
Stanford University
研究点 (1)
Loading locations...
相似试验
撤回
1 期
Phase I/II Study of Intratumoral Injection of CPG 7909, a TLR9 Agonist, Combined With Local Radiation for Patients With Recurrent Mycosis Fungoides.Mycosis FungoidesNCT00226993Stanford University
撤回
1 期
Dendritic Cell Vaccine for Head and Neck CancerSquamous Cell Carcinoma of Head and NeckNCT00492947University of Maryland, Baltimore
招募中
1 期
A phase I/IIa clinical study of BT-001 in the treatment of patients withmetastatic or advanced solid cancer.Phase I: Advanced or metastatic solid tumors including Non-Hodgkin Lymphoma (NHL) and preferably Soft Tissue Sarcoma, Merkel Cell Carcinoma, Melanoma, Triple Negative Breast Cancer, Non Smal Cell Lung Cancer Phase IIa: Soft Tissue Sarcoma, Merkel Cell Carcinoma, Melanoma, Triple Negative Breast Cancer, Non Smal Cell Lung CancerMedDRA version: 21.1Level: LLTClassification code 10065252Term: Solid tumorSystem Organ Class: 100000004864EUCTR2020-000505-80-FRTRANSGENE48
进行中（未招募）
1 期
A phase I/IIa clinical study of BT-001 in the treatment of patients withmetastatic or advanced solid cancer.Phase I: Advanced or metastatic Soft Tissue Sarcoma, Merkel Cell Carcinoma, Melanoma, Triple Negative Breast Cancer, Non Smal Cell Lung Cancer Phase IIa: Soft Tissue Sarcoma, Merkel Cell Carcinoma, Melanoma, Triple Negative Breast Cancer, Non Smal Cell Lung CancerMedDRA version: 21.1Level: LLTClassification code 10065252Term: Solid tumorSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-000505-80-BETRANSGENE258
终止
1 期
VTX-2337 in Combination With Radiotherapy in Patients Low-Grade B-cell LymphomasLow Grade B Cell LymphomaNCT01289210Celgene2